Biperiden(KL 373) Hcl is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker.
Target: M1 receptors
Biperiden is an antiparkinsonian agent of the anticholinergic type. It is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic, idiopathic, and arteriosclerotic). Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervate. It also has a prominent central blocking effect on M1 receptors.
Biperiden (0.11 mg/kg), benactyzine (0.3 mg/kg),caramiphen (10 mg/kg), procyclidine (3 mg/kg), and trihexyphenidyl (0.12 mg/kg) separately and each in combination with physostigmine (0.1 mg/kg) is  to make a comparative assessment of potential cognitive effects. The results showed that benactyzine, caramiphen, and trihexyphenidyl reduced rats' innate preference for novelty, whereas biperiden and procyclidine did not.
Clinical indications: parkinsonism
FDA Approved Date:
Toxicity: Drowsiness; vertigo; headache; dizziness

mAChR
Cevimeline
Darifenacin
Diphenmanil methylsulfate
Fesoterodine fumarate
Flavoxate hydrochloride
Gallamine Triethiodide
Glycopyrrolate
Homatropine Bromide
Ipratropium bromide
Irsogladine
L-Hyoscyamine
mAChR-IN-1
Methscopolamine bromide